We have located links that may give you full text access.
CLINICAL TRIAL
COMPARATIVE STUDY
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
RESEARCH SUPPORT, NON-U.S. GOV'T
A comparative study of the efficacy of Aphtheal in the management of recurrent minor aphthous ulceration.
Journal of Oral Pathology & Medicine 2005 August
BACKGROUND: Recurrent minor aphthous ulceration (RAU) is a common condition which is multifactorial in origin.
METHODS: This study, firstly, aimed to treat the prodromal stage of RAU with Aphtheal (5% amlexanox paste) to determine if ulcer development could be prevented. A second arm of the study investigated treatment of RAU with Aphtheal once ulceration had developed. Ulcer duration, ulcer size and associated pain were measured. Both groups of subjects had previously undergone a no-treatment run-in period to establish these parameters over an untreated episode of ulceration.
RESULTS: By day 3, only 35% of the prodromal group had developed an ulcer compared with 97% of the ulcer group (P < 0.001). In the treated ulcer group only 66% had an ulcer present by day 3. Treatment at the onset of prodromal symptoms reduced the maximum ulcer size score by 84% (P < 0.01), extent of ulceration by 88% (P < 0.01), maximum pain score by 69% (P < 0.01) and extent of pain by 85% (P < 0.01) compared to no treatment.
CONCLUSION: Treatment with Aphtheal at the onset of prodromal RAU symptoms can prevent progression to ulcer development and significantly reduced symptoms if ulcers do develop.
METHODS: This study, firstly, aimed to treat the prodromal stage of RAU with Aphtheal (5% amlexanox paste) to determine if ulcer development could be prevented. A second arm of the study investigated treatment of RAU with Aphtheal once ulceration had developed. Ulcer duration, ulcer size and associated pain were measured. Both groups of subjects had previously undergone a no-treatment run-in period to establish these parameters over an untreated episode of ulceration.
RESULTS: By day 3, only 35% of the prodromal group had developed an ulcer compared with 97% of the ulcer group (P < 0.001). In the treated ulcer group only 66% had an ulcer present by day 3. Treatment at the onset of prodromal symptoms reduced the maximum ulcer size score by 84% (P < 0.01), extent of ulceration by 88% (P < 0.01), maximum pain score by 69% (P < 0.01) and extent of pain by 85% (P < 0.01) compared to no treatment.
CONCLUSION: Treatment with Aphtheal at the onset of prodromal RAU symptoms can prevent progression to ulcer development and significantly reduced symptoms if ulcers do develop.
Full text links
Trending Papers
Cardiovascular Disease in Diabetes and Chronic Kidney Disease.Journal of Clinical Medicine 2023 November 9
Monitoring Macro- and Microcirculation in the Critically Ill: A Narrative Review.Avicenna Journal of Medicine 2023 July
Urinary tract infections: a review of the current diagnostics landscape.Journal of Medical Microbiology 2023 November
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app